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Abstract. The aim of the present study was to elucidate the 
associations between the expression of the vascular endothelial 
growth factor-C (VEGF-C)/VEGF receptor-3 (VEGFR-3) axis 
and lymphangiogenesis, regional lymph node metastasis and 
clinicopathological factors in oral tongue squamous cell carci-
noma (OTSCC) using immunohistochemistry. The expression 
of VEGF-C, VEGFR-3 and podoplanin was immunohisto-
chemically evaluated in specimens obtained from 65 patients 
with OTSCC (T1-2, N0) who had undergone radical surgery 
alone. The associations between the expression of VEGF-C, 
VEGFR-3 and podoplanin, and lymphangiogenesis, regional 
lymph node metastasis and clinocopathological factors were 
determined by immunohistochemical analysis. VEGF-C, 
VEGFR-3 and combined VEGF-C/VEGFR-3 expression was 
significantly higher in cases with regional recurrence compared 
with those without lymph node involvement (P<0.001). As 
regards lymphangiogenesis, a significant correlation was 
observed between podoplanin expression and VEGF-C, 
VEGFR-3 and combined VEGF-C/VEGFR-3 expression 
(P<0.001). Therefore, lymphangiogenesis in the peritumoral 
stroma was associated with lymph node metastasis. However, 
podoplanin expression did not exhibit a significant correlation 
with the progression of lymph node metastasis. The results 
of the present study suggest that the VEGF-C/VEGFR-3 
axis may be associated with lymph node metastasis through 
lymphangiogenesis. Determining the VEGF-C/VEGFR-3 
expression status may help predict which patients will develop 
regional recurrence and provide novel targets for therapies to 
suppress lymph node metastasis in the treatment of OTSCC.
Introduction
Oral tongue squamous cell carcinoma (OTSCC) accounts 
for ~1.5% of all cancer cases and is an aggressive cancer, 
frequently associated with a poor prognosis (1,2). The 5-year 
disease‑specific survival (DSS) rate for patients with OTSCC 
has remained at 50-70% over the last 20 years (2-4). The 
current management and treatment of OTSCC for the majority 
of patients is surgery, with generally promising outcomes (4,5). 
In patients with early-stage OTSCC (T1-2, N0), the reported 
5-year survival rates range between 75 and 89% (2,6,7). Inter-
stitial brachytherapy is considered to be a viable treatment 
option for patients with early-stage OTSCC, since it results in 
a better functional preservation of swallowing and articulation 
compared with surgery and is associated with a satisfactory 
local control rate (8). However, certain patients with early-stage 
OTSCC may have a poor prognosis due to lymph node metas-
tasis. Over 30% of patients with OTSCC exhibit cervical 
lymph node metastases, even in clinically node-negative 
disease. Among patients with early-stage OTSCC, the regional 
recurrence rate of the untreated neck is 20-30% (3,9). However, 
there remains controversy regarding the treatment of the clini-
cally negative neck in such patients (10). Therefore, the role of 
the lymphatic system in OTSCC metastasis must be elucidated.
Although regional lymph node metastasis represents the 
first step of tumor dissemination for a variety of common 
types of human cancer, the molecular mechanisms underlying 
lymphatic metastasis are incompletely understood (11-13). 
Lymph node metastasis may be caused by the invasion of tumor 
cells in pre-existing lymphatic vessels in the tumor periphery, 
or through the induction of lymphangiogenesis via growth 
factor production (11,12,14). Lymphangiogenic growth factors 
produced by tumor cells and tumor-associated macrophages 
stimulate growth and dilation of the peritumoral lymphatic 
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vessels and facilitate tumor cell entry through the lymphatic 
endothelium (11,13). Vascular endothelial growth factor-C 
(VEGF-C) is one of the lymphangiogenic growth factors of the 
platelet-derived growth factor/VEGF family. VEGF-C is an 
essential chemotactic and survival factor during embryonic and 
inflammatory lymphangiogenesis. VEGF‑C is predominantly 
expressed along with VEGF receptor-3 (VEGFR-3), mainly 
in lymphatic capillaries, where it activates the development of 
tumor-associated lymphatic vessels and facilitates the access 
of tumor cells into these vessels (13-16). Several studies have 
reported that the VEGF-C/VEGFR-3 axis is associated with 
lymph node metastasis and that its expression is a prognostic 
factor for various cancers of the esophagus (17,18), stomach (19), 
colorectum (20), lung (21), cervix (22,23), prostate (24) and 
head and neck (25). Increasing evidence suggests that the 
VEGF-C/VEGFR-3 axis is associated with lymphangiogenesis, 
regional lymph node metastasis and poor prognosis. However, 
the role of the VEGF-C/VEGFR-3 axis in OTSCC has yet to be 
examined in detail. In the present study, immunohistochemical 
staining was used to investigate whether the expression of 
VEGF-C and VEGFR-3 is associated with lymphangiogenesis, 
regional lymph node metastasis and clinocopathological factors.
Materials and methods
Patients. The records of 65 patients who underwent radical 
surgery alone for early-stage (T1-2, N0) OTSCC between 
January, 2001 and December, 2011 were retrospectively 
reviewed. Paraffin‑embedded sections of resected specimens 
were obtained (26). Tumor staging was performed according 
to the TNM classification of the International Union Against 
Cancer (27). Histological differentiation was defined according to 
the World Health Organization classification. The pattern of inva-
sion (POI) was classified according to Bryne's classification (28).
All the study patients underwent extensive pretreatment 
evaluation, including physical examination, computed tomog-
raphy (CT), magnetic resonance imaging, ultrasonography and 
positron emission tomography/CT for cervical lymph node 
metastasis. Patients diagnosed with no cervical lymph node 
involvement do not routinely undergo elective neck dissection; 
however, 4 patients in the present study had undergone neck 
dissection due to reconstruction, of whom 2 patients were found 
to have pathological occult cervical lymph node metastasis, 
which was defined as regional recurrence. Regional recurrence 
was defined as disease recurrence in the neck alone. Previous 
studies have demonstrated that the depth of invasion (DOI) 
is of predictive value for lymph node metastasis in patients 
with T1-2, N0 OTSCC (29-33). In the present study, DOI was 
classified into two groups, namely the ≥4 and <4 mm groups.
Immunohistochemical staining and evaluation. Sections 
deparaffinized in xylene were soaked in 10 mmol/l citrate 
buffer (pH 6.0) and placed in an autoclave at 121˚C for 5 min 
for antigen retrieval. Endogenous peroxidase was blocked by 
incubation with 0.3% H2O2 in methanol for 30 min. Immunohis-
tochemical staining was performed using the EnVision system 
(EnVision™+; Dako, Glostrup, Denmark). The following 
primary antibodies were used: Rabbit polyclonal antibodies 
against VEGF-C (cat. no. 18-2255; Invitrogen Life Tech-
nologies, Carlsbad, CA, USA; dilution, 1:100) and VEGFR-3 
(cat. no. ab27278; Abcam, Cambridge, UK; dilution, 1:200). 
The sections were washed in Dulbecco's phosphate‑buffered 
saline (PBS; Wako Pure Chemical Industries, Ltd., Osaka, 
Japan), followed by incubation with the primary antibodies 
at 4˚C overnight. The reaction products were visualized by 
immersing the sections in diaminobenzidine solution and the 
samples were counterstained with Mayer's hematoxylin (Wako 
Pure Chemical Industries, Ltd.) and mounted.
VEGF-C protein expression was evaluated by calculating 
the total immunostaining score as the product of the propor-
tional and the intensity scores. As previously described (25,34), 
Table I. Clinicopathological characteristics of patients with 
oral tongue squamous cell carcinoma (n=65).
Characteristics No. (%)
Age (years)
  Range 28-86
  Mean 64.2
Gender
  Male 35 (53.8)
  Female 30 (46.2)
T stage
  T1 38 (58.5)
  T2 27 (41.5)
Clinical growth pattern
  Superficial 27 (41.5)
  Exophytic 12 (18.5)
  Endophytic 26 (40.0)
Histological differentiation
  High 62 (95.4)
  Moderate 2 (3.1)
  Poor 1 (1.5)
Depth of invasion (mm)
  <4 42 (64.6)
  ≥4 23 (35.4)
Pattern of invasion
  Grade 1   7 (10.8)
  Grade 2 49 (75.4)
  Grade 3   8 (12.3)
  Grade 4 1 (1.5)
Neck treatment
  Observation 61 (93.8)
  Dissection 4 (6.2)
Regional recurrence
  No 52 (80.0)
  Yes 13 (20.0)
pN classification
  pN1   8 (61.5)
  pN2   5 (38.5)
Extracapsular spread
  Negative   6 (46.2)
  Positive   7 (53.8)
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proportional scores are based on the estimated fraction of 
positively-stained tumor cells (0, none; 1, <10%; 2, 10-50%; 
3, 50-80%; and 4, >80%). The intensity score represents 
the estimated staining intensity (0, no staining; 1, weak; 
2, moderate; and 3, strong). Therefore, the total immunos-
taining score ranges between 0 and 12. Positive cases were 
defined as those with a total score of >4, as the patient samples 
exhibited a bimodal distribution of immunohistochemical 
expression, where the discriminating nadir was a total score 
value of 3‑4. VEGFR‑3 staining was defined as positive if 
the vessel structures in the tumor stroma were highlighted. 
If no vessel structure was highlighted in the tumor stroma, 
the specimen was classified as negative. The evaluation of 
the combined VEGF-C/VEGFR‑3 expression was classified 
into two categories: If the VEGF-C expression score was 0-3 
and VEGFR-3 expression was negative, VEGF-C/VEGFR-3 
expression was considered to be negative. If either the 
VEGF-C expression score was >4 or VEGFR-3 was positive, 
VEGF-C/VEGFR-3 expression was considered to be positive.
Lymphatic vessels were highlighted by staining lymphatic 
endothelial cells with mouse monoclonal antibody against 
podoplanin (cat. no. DK-2600; Dako; dilution, 1:100) and the 
number of lymphatic vessels was counted according to the 
hot-spot method (9,34). In brief, the area of highest lympho-
vascular density in the peritumoral stroma was identified by 
examining hematoxylin and eosin-stained sections under a 
Leica DM500 light microscope (Leica Microsystems, Inc.- 
Buffalo Grove, IL, USA; magnification, x200). The total 
number of lymphatic vessels in each of three visual fields was 
counted and the mean values were calculated. All immunohis-
tochemical assessments were performed by two examiners in a 
blinded manner.
Statistical analysis. The associations between the expression 
of target molecules and clinicopathological characteristics 
were analyzed by the Fisher's exact test. Continuous data are 
presented as means ± standard deviation. The DSS rate was 
calculated by the Kaplan-Meier method and compared using 
the log-rank test. A multiple regression study was performed 
using Cox proportional hazards analysis. Predictors that 
were not associated with DSS or lymph node metastasis were 
not included in the multivariate analysis. The difference in 
Figure 1. Representative immunohistochemical staining for VEGF-C, VEGFR-3 and podoplanin. (A) Negative staining for VEGF-C in OTSCC. (B) OTSCC 
with Bryne's score 2, displaying strong VEGF-C cytoplasmic expression (staining index, 12). Negative staining for VEGFR-3 (C) in the peritumoral stroma 
and (D) at the invasive front. Podoplanin expression (E) in the peritumoral stroma and (F) at the invasive front. VEGF-C, vascular endothelial growth factor-C; 
VEGFR-3, vascular endothelial growth factor receptor-3; OTSCC, oral tongue squamous cell carcinoma.
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podoplanin expression between the groups was evaluated by 
the Student's t‑test. P<0.05 was considered to indicate a statis-
tically significant difference.
Results
Patient characteristics. The clinicopathological character-
istics of the patients are summarized in Table I. Between 
2001 and 2011, a total of 65 patients were evaluated 53.8% 
of whom were male and 46.2% female. The mean age of 
the patients was 64.2 years (range, 28-86 years). The 
regional recurrence rate was 20% (13/65 patients) during 
the follow-up period; of these, 8 cases were pN1 and 
5 were pN2. Of the 65 cases, 7 were extracapsular spread 
(ECS)-positive.
Expression of VEGF‑C, VEGFR‑3 and podoplanin 
in OTSCC. Among the 65 patients with OTSCC, the 
immunohistochemical staining was positive for VEGF-C 
in 78.4% and for VEGFR-3 in 55.4% of the samples. 
VEGF-C was expressed primarily in the cytoplasm of 
the tumor cells, with the intensity ranging between weak 
and strong. The distribution of VEGF-C was observed in 
tumor nests and at the invasive front, with particularly 
strong expression observed at the invasive front (Fig. 1A 
and B). In the peritumoral stroma, VEGFR-3-positive 
small-diameter lymphatic vessels were observed (Fig. 1C 
and D). Podoplanin was expressed in the microvas-
cular structures and the cytoplasm of tumor cells, with 
podoplanin-positive microvascular structures clearly 
detected in the peritumoral stroma and connective tissue. 
Podoplanin expression was absent in tumor nests and 
was found only in the basal cell layer, with diffuse and 
extensive expression in the cytoplasm of the tumor cells 
(Fig. 1E and F).
Associations of VEGF‑C and VEGFR‑3 expression with 
clinicopathological characteristics and survival. VEGF-C 
and VEGFR-3 expression in OTSCC was investigated as 
a function of clinicopathological characteristics. VEGF-C 
expression was significantly associated with clinical growth 
pattern (P<0.01) and DOI (P<0.05). There was no significant 
association between VEGF-C expression and POI or regional 
recurrence. VEGFR‑3 expression was significantly associated 
Table II. Associations of VEGF-C and VEGFR-3 expression with clinicopathological factors.
 VEGF-C expression VEGFR-3 expression
 --------------------------------------- -----------------------------------------
Characteristics - + P-value - + P-value
Age (years)   0.257   0.209
  >65  5 24  10 19
  ≤65 11 25  19 17
Gender   0.5660   1.000
  Male  0 25  16 19
  Female  6 24  13 17
T stage   0.152   0.324
  T1 + T2 12 26  19 19
  T3 + T4   4 23  10 17
Differentiation   1.00   1.000
  High 16 46  28 28
  Moderate/poor   0   3    1   8
Pattern of invasion   0.569   0.036
  Grades 1/2 15 41  28 28
  Grades 3/4   1   8    1   8
Clinical growth pattern   0.0012   0.0056
  Superficial + exophytic 15 24  23 16
  Endophytic   1 25    6 20
Regional recurrence    0.159   0.027
  No 15 37  27 25
  Yes   1 12    2 11
Depth of invasion (mm)   0.0052   0.0088
  <4 15 27  24 18
  ≥4   1 22    5 18
VEGF-C, vascular endothelial growth factor-C; VEGFR-3, vascular endothelial growth factor receptor-3.
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with clinical growth pattern, POI, DOI and regional recur-
rence (P<0.01, <0.05, <0.01 and <0.05, respectively) (Table II). 
Combined VEGF-C/VEGFR‑3 expression was significantly 
associated with clinical growth pattern, DOI and regional 
recurrence (P<0.001, <0.001 and <0.05, respectively) 
(Table III).
The 5-year DSS rate according to the combined 
VEGF-C/VEGFR-3 expression was determined. The univar-
iate analysis using the log-rank test and the Kaplan-Meier 
method demonstrated that combined VEGF-C/VEGFR-3 
expression was likely to be associated with 5-year DSS, but 
no significant difference was observed between positive and 
negative cases (Fig. 2, P=0.139).
Association of VEGF‑C and VEGFR‑3 expression with regional 
recurrence. The univariate logistic analysis revealed a signifi-
cant association of regional recurrence with T stage (P=0.03), 
clinical growth pattern (P<0.01), POI (P<0.001), DOI (P<0.001) 
and VEGF-C/VEGFR-3 (P=0.043) (Table IV). A multivariate 
logistic regression analysis was performed for each predictor of 
regional recurrence, and VEGF-C/VEGFR-3 was not identified 
as an independent factor for regional recurrence (Table V).
Association of lymphatic vessel count with the expression 
of VEGF‑C/VEGFR‑3 and the progression of pathological 
lymph node metastasis. A significant association was 
observed between combined VEGF-C/VEGFR-3 expres-
sion and lymphatic vessel count (P<0.001). Furthermore, 
when VEGF-C/VEGFR-3-positive and -negative cases were 
compared, the lymphatic vessel count was significantly higher 
in VEGF-C/VEGFR-3-positive cases (P<0.001). Lymph node 
metastasis was subdivided into two groups: 13 cases were 
classified as pN0 and 52 cases as pN1-2. The mean lymphatic 
vessel count was significantly higher in the pN‑positive group 
compared with that in the pN-negative group (P<0.0001). 
For further analysis, the pN-positive group was subdivided 
into four categories, namely pN1, pN2, ECS-negative and 
ECS-positive, in order to investigate the correlation between 
the progression of lymph node metastasis and lymphan-
giogenesis. However, no significant correlation was observed 
(Table VI).
Discussion
Further insight regarding VEGF-C/VEGFR-3 expression in 
OTSCC may improve our understanding of lymphangiogenesis 
and regional lymph node metastasis, in addition to providing 
novel treatment possibilities for OTSCC. Therefore, the 
present study aimed to determine the expression of molecules 
associated with lymphangiogenesis, lymph node metastasis 
and survival rate in OTSCC.
VEGF-C expression was found to be associated with 
clinical growth pattern and DOI, whereas the expression 
of VEGFR-3 was associated with POI, clinical growth 
pattern, regional recurrence and DOI. The expression of the 





Characteristics - + P-value
Age (years)   0.605
  >65   9 20
  ≤65 14 22
Gender   0.799
  Male 13 22
  Female 10 20
T stage   0.408
  T1 + T2 17 21
  T3 + T4   6 21
Differentiation    0.546
  High 23 39
  Moderate/poor   0   3
Pattern of invasion   0.142
  Grades 1/2 22 34
  Grades 3/4   1   8
Clinical growth pattern   0.0001
  Superficial + exophytic 21 18
  Endophytic   2 24
Regional recurrence   0.0235
  No 22 30
  Yes   1 12
Depth of invasion (mm)   0.0009
  <4 21 21
  ≥4   2 21
VEGF-C, vascular endothelial growth factor-C; VEGFR-3, vascular 
endothelial growth factor receptor-3.
  
Figure 2. Kaplan-Meier survival curve of the 5‑year DSS rate. No significant 
correlation between VEGF-C/VEGFR-3-positive and -negative patients was 
observed regarding the 5-year DSS rate (P=0.139). Differences between the 
two groups were evaluated by the log‑rank test. DSS, disease‑specific sur-
vival; VEGF-C, vascular endothelial growth factor-C; VEGFR-3, vascular 
endothelial growth factor receptor-3.
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VEGF-C/VEGFR-3 axis was found to be associated with 
clinical growth pattern, regional recurrence and DOI, but 
not with 5-year DSS. Furthermore, the expression of the 
VEGF-C/VEGFR-3 axis was found to be predictive of regional 
recurrence (odds ratio = 8.8), T stage (T2), diffuse POI, endo-
phytic growth pattern and DOI (≥4 mm) in the univariate 
analysis. These results suggest that the VEGF-C/VEGFR-3 
axis may be associated with the mechanism of regional recur-
rence in OTSCC.
Previous studies denonstrated that VEGF-C and VEGFR-3 
expression is significantly associated with lymph node metas-
tasis in esophageal SCC, gastric, cervical and head and neck 
cancer (17-19,22,25). Furthermore, VEGF-C and VEGFR-3 
expression was found to be significantly associated with poor 
survival rates in patients with esophageal SCC and gastric 
carcinoma (18,19). However, two previous studies reported no 
association between VEGF-C and VEGFR-3 expression and 
lymph node metastasis in lung and colorectal cancer (20,21). 
These differences in study findings may be due to the 
different anatomical locations of the tumors, differences in 
the study method, or differences in the cut-off value for posi-
tivity. However, high-intensity expression was observed at the 
invasive front in the present study, indicating that VEGF-C 
and VEGFR-3 play a major role in lymph node metastasis in 
OTSCC. The significant correlation between the expression 
of the VEGF-C/VEGFR-3 axis and 5-year DSS may be attrib-
uted to the present study focusing on early-stage OTSCC.
It has been reported that lymphangiogenesis is associated 
with lymph node metastasis, as peritumoral lymphatics located 
immediately adjacent to tumors or in the peritumoral stroma 
may be dilated or enlarged (11-13). A number of previous 
studies have used podoplanin or other lymphatic markers 
to verify this association (9,13,18,25,35,36). However, it has 
been reported that intratumoral lymphatic vessels may be 
poorly functional and not required for lymph node metas-
tasis, as tumor cells may spread via pre-existing lymphatic 
vessels (11-13,37). Podoplanin, a mucin-like transmembrane 
glycoprotein, is one of the specific markers of lymph vessel 
endothelial cells. Podoplanin is highly and specifically 
expressed in the endothelial cells of lymphatic vessels, but not 
in those of blood vessels (36). Although its biological function 
is not yet clearly understood, a number of previous reports have 
suggested that podoplanin may act as a mediator of tumor cell 
invasion and metastasis (9,13,18,25,35,37). However, a previous 




Characteristics - + Odds ratio 95% CI P-value
Age (years)   0.628 0.185-2.13 0.456
  >65 22  7
  ≤65 30  6
Gender   2.250 0.615-8.23 0.221
  Male 26  9
  Female 26  4
T stage   4.250 1.148-15.73 0.031
  T1 34  4
  T2 18  9
Differentiation   9.270 0.770-111.54 0.079
  High 51 11
  Moderate/poor   1  2
Pattern of invasion   81.600 8.400-791.90 <0.001
  Grades 1/2 47 5
  Grades 3/4   5  8
Clinical growth pattern   32.570 3.800-274.10 <0.010
  Superficial + exophytic 38   1
  Endophytic 14 12
Depth of invasion (mm)   44.700 5.200-382.40 <0.001
  <4 41   1
  ≥4 11 12
VEGF-C/VEGFR-3   8.800 1.060-72.79 0.024
  Negative 22   1
  Positive 30 12
VEGF‑C, vascular endothelial growth factor‑C; VEGFR‑3, vascular endothelial growth factor receptor‑3; CI, confidence interval.
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study reported no significant correlation between podoplanin 
expression and tumor metastasis (37). Evidence regarding 
podoplanin expression in OTSCC, in particular, has demon-
strated that the immunoreactivity to podoplanin is 97% and 
its expression exerts no effect on T stage (38). Therefore, the 
present study investigated the association of podoplanin with 
the VEGF-C/VEGFR-3 axia and the progression of lymph 
node metastasis.
The present study showed that the expression of podoplanin 
was clearly distributed in the peritumoral stroma and cytoplasm 
of tumor cells. The number of lymphatic vessels highlighted 
by podoplanin expression was associated with lymph node 
metastasis. Furthermore, the presence of VEGF-C, VEGFR-3 
and the VEGF-C/VEGFR-3 axis was associated with an 
increased lymphatic vessel count, but not with the progression of 
lymph node metastasis. These results suggested that peritumoral 
lymphatic vessels may be functional and that lymphangiogen-
esis is associated with lymph node metastasis. It was previously 
demonstrated that podoplanin expression predicts the progres-
sion of lymph node metastasis (37). However, in the present 
study, no significant association with the progression of lymph 
node metastasis was observed. From these results, it may be 
hypothesized that podoplanin is a useful marker for predicting 
lymph node metastasis, but is of less value for predicting the 
progression of lymph node metastasis.
The hot-spot method is frequently used to count the lymphatic 
vessels highlighted by podoplanin expression (9,18,25,35,37). 
It was recently reported that podoplanin expression in tumor 
cells is associated with tumorigenesis in OSCC (36). Therefore, 
further investigation is required to determine the utility of 
evaluating podoplanin expression in patients with OTSCC.
The present study revealed that the VEGF-C/VEGFR-3 
pathway is associated with lymph node metastasis through 
lymphangiogenesis. A potential limitation of the present 
study is its retrospective design. This type of study may be 
associated with inherent bias. In our department, resectable 
OTSCC is currently treated with surgery and/or adjuvant 
chemoradiotherapy to reduce the risk of recurrence. Patients 
who required neoadjuvant radiotherapy and/or chemotherapy, 
and who exhibited more advanced, unresectable disease, 
were excluded from the present study. Despite unifying the 
surgical modality, residual confounding may have occurred. 
Therefore, prospective study design is required to increase 
the evidence of the present study. Finally, since the incidence 
of OTSCC is low compared with other types of cancer, the 
present study included a small number of cases. Therefore, 
further intergroup studies are required to confirm our results. 
In conclusion, although the association between lymphan-
giogenesis and lymph node metastasis is controversial, 
determining the status of VEGF-C/VEGFR-3 expression may 
help predict which patients are at risk of developing regional 
recurrence and provide a novel target for the treatment of 
OTSCC through the suppression of lymph node metastasis.
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